Company intelligence / Profile preview
Auricula Biosciences
Wilmington, Delaware, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Auricula Biosciences is developing a first-in-class targeted therapeutic (SDV-1001) designed as a pan-KRAS approach to address all KRAS mutations and overcome resistance mechanisms found in conventional inhibitors; the therapy is preclinical and aims to enter first-in-human Phase 1/2a studies in K-RAS mutant cancers, addressing unmet need for broad and durable efficacy in KRAS-driven malignancies[3][5][6][7].
- Therapeutic areas
- Oncology
- Modalities
- Small moleculeConjugate
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
SyndiviaTVM Capital Life ScienceEli Lilly
Beyond the preview
Go deeper on Auricula Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Auricula Biosciences.